ORPHA:213787
Carcinosarcoma of the cervix uteri
Also known as: Cervical carcinosarcoma · Cervical malignant Müllerian mixed tumor · Malignant Müllerian mixed tumor of the cervix uteri
Publications
83
48th percentile
Trials
1
Interventional, condition-specific
Researchers
506
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Carcinosarcoma of the cervix uteri is a rare, malignant, mixed epithelial and mesenchymal tumor, located in the cervix uteri, composed of an admixture of carcinomatous and sarcomatous elements. It usually presents with abnormal vaginal bleeding and a round, well-defined, grey to yellowish-white, pedunculated polypoid mass protruding through the cervical canal. Association with HPV infection (especially serotype 16) has been frequently reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0002877
- UMLS:C1332917
- NCIT:C36097
Additional Mondo synonyms (17)
carcinosarcoma of the cervix uteri · cervical carcinosarcoma · cervical malignant Mullerian mixed tumor · cervical malignant Mullerian mixed tumour · cervical malignant Müllerian mixed tumor · cervical malignant Müllerian mixed tumour · cervical malignant mixed Mullerian tumour · cervical malignant mixed mesodermal (Mullerian) tumor · cervical malignant mixed mesodermal (Mullerian) tumour · cervical malignant mixed mesodermal (Müllerian) tumor · cervical malignant mixed mesodermal (Müllerian) tumour · cervical malignant mixed mesodermal mullerian tumour · malignant Mullerian mixed tumor of the cervix uteri · malignant Mullerian mixed tumour of the cervix uteri · malignant Müllerian mixed tumor of the cervix uteri · malignant Müllerian mixed tumour of the cervix uteri · uterine cervix carcinosarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
83 matched papers (52 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
83
83 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
83 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
52 in the last 10 years · high confidence · 48th percentile (publications denominator)
Phrase hits: 83 · MeSH hits: 0
Who's working on it?
506
Distinct author names in 83 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Hayashi T3 papers · 2025
1Cancer Medicine, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan.
Papers in Europe PMC - 02Li L3 papers · 2025
Department of Radiology, The First Affiliated Hospital of Zhengzhou University, No. 1, East Jianshe Road, Zhengzhou, 450052, Henan, China.
Papers in Europe PMC - 03
- 04Yasuda M3 papers · 2019
Departments of Pathology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1128, Japan
Papers in Europe PMC - 05Abiko K2 papers · 2025
2Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Ishikawa, 920-8641, Japan.
Papers in Europe PMC - 06Albert A2 papers · 2020
Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA. ashley.grv@gmail.com.
Papers in Europe PMC - 07Georgescu TA2 papers · 2021
Discipline of Pathology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Papers in Europe PMC - 08
- 09Konishi I2 papers · 2025
3Department of Obstetrics and Gynecology, Kyoto University School of Medicine, Kyoto 606-8507 Japan.
Papers in Europe PMC - 10Lee JW2 papers · 2023
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 83 trials are registered for carcinosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
high confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: carcinosarcoma
83
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT03422198·RECRUITING·Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
Not reviewed·Conditions: Endometrial Clear Cell Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma · Stage I Uterine Corpus Cancer·Matched via name phrase
- NCT05902988·RECRUITING·A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Not reviewed·Conditions: Advanced Solid Tumor · High Grade Serous Adenocarcinoma of Ovary · Squamous Non-small-cell Lung Cancer · Triple Negative Breast Cancer·Matched via name phrase
- NCT05559879·RECRUITING·Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Not reviewed·Conditions: Gynecologic Cancer · Carcinoma · Uterine Cancer · Endometrial Cancer·Matched via name phrase
- NCT06639074·RECRUITING·Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Not reviewed·Conditions: Advanced Fallopian Tube Carcinoma · Advanced Fallopian Tube High Grade Serous Adenocarcinoma · Advanced Ovarian Carcinoma · Advanced Ovarian Carcinosarcoma·Matched via name phrase
- NCT07723235·NOT YET RECRUITING·Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial
Not reviewed·Conditions: Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Endometrial Carcinoma·Matched via name phrase
- NCT04919629·RECRUITING·APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Not reviewed·Conditions: Fallopian Tube Carcinosarcoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Not reviewed·Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT05269381·RECRUITING·Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Not reviewed·Conditions: Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IIIA Breast Cancer AJCC v8 · Anatomic Stage IIIB Breast Cancer AJCC v8 · Anatomic Stage IIIC Breast Cancer AJCC v8·Matched via name phrase
- NCT05646316·RECRUITING·Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Not reviewed·Conditions: Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8·Matched via name phrase
- NCT05920798·RECRUITING·Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Not reviewed·Conditions: Fallopian Tube Carcinosarcoma · Primary Peritoneal Carcinosarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Clear Cell Adenocarcinoma·Matched via name phrase
- NCT05542407·RECRUITING·ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Not reviewed·Conditions: Endometrial Cancer · Metastasis · Endometrioid Endometrial Cancer · Carcinosarcoma·Matched via name phrase
- NCT05619913·RECRUITING·EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Not reviewed·Conditions: Ovarian Carcinosarcoma · Uterine Carcinosarcoma·Matched via name phrase
- NCT03651206·RECRUITING·Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Not reviewed·Conditions: Ovarian Carcinosarcoma · Endometrial Carcinosarcoma·Matched via name phrase
- NCT06483048·RECRUITING·MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Not reviewed·Conditions: Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma·Matched via name phrase
- NCT05256225·RECRUITING·Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Not reviewed·Conditions: Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Carcinosarcoma of the cervix uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Carcinosarcoma of the cervix uteri" OR "Carcinosarcoma of cervix uteri" OR "Cervical carcinosarcoma" OR "Cervical malignant Müllerian mixed tumor" OR "Malignant Müllerian mixed tumor of the cervix uteri" OR "Malignant Müllerian mixed tumor of cervix uteri" OR "cervical malignant Mullerian mixed tumor" OR "cervical malignant Mullerian mixed tumour" OR "cervical malignant Müllerian mixed tumour" OR "cervical malignant mixed Mullerian tumour" OR "cervical malignant mixed mesodermal (Mullerian) tumor" OR "cervical malignant mixed mesodermal (Mullerian) tumour" OR "cervical malignant mixed mesodermal (Müllerian) tumor" OR "cervical malignant mixed mesodermal (Müllerian) tumour" OR "cervical malignant mixed mesodermal mullerian tumour" OR "malignant Mullerian mixed tumor of the cervix uteri" OR "malignant Mullerian mixed tumor of cervix uteri" OR "malignant Mullerian mixed tumour of the cervix uteri" OR "malignant Mullerian mixed tumour of cervix uteri" OR "malignant Müllerian mixed tumour of the cervix uteri" OR "malignant Müllerian mixed tumour of cervix uteri" OR "uterine cervix carcinosarcoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Carcinosarcoma of the cervix uteri" OR "Carcinosarcoma of cervix uteri" OR "Cervical carcinosarcoma" OR "Cervical malignant Müllerian mixed tumor" OR "Malignant Müllerian mixed tumor of the cervix uteri" OR "Malignant Müllerian mixed tumor of cervix uteri" OR "cervical malignant Mullerian mixed tumor" OR "cervical malignant Mullerian mixed tumour" OR "cervical malignant Müllerian mixed tumour" OR "cervical malignant mixed Mullerian tumour" OR "cervical malignant mixed mesodermal (Mullerian) tumor" OR "cervical malignant mixed mesodermal (Mullerian) tumour" OR "cervical malignant mixed mesodermal (Müllerian) tumor" OR "cervical malignant mixed mesodermal (Müllerian) tumour" OR "cervical malignant mixed mesodermal mullerian tumour" OR "malignant Mullerian mixed tumor of the cervix uteri" OR "malignant Mullerian mixed tumor of cervix uteri" OR "malignant Mullerian mixed tumour of the cervix uteri" OR "malignant Mullerian mixed tumour of cervix uteri" OR "malignant Müllerian mixed tumour of the cervix uteri" OR "malignant Müllerian mixed tumour of cervix uteri" OR "uterine cervix carcinosarcoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"carcinosarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:39:04.825Z